Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8


Diagnosis and Treatment of Plasmodium vivax Malaria.

Baird JK, Valecha N, Duparc S, White NJ, Price RN.

Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):35-51. doi: 10.4269/ajtmh.16-0171. Epub 2016 Oct 5.


OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.

Aljayyoussi G, Kay K, Ward SA, Biagini GA.

Malar J. 2016 Jul 7;15(1):344. doi: 10.1186/s12936-016-1401-8.


Advances in the treatment of malaria.

Castelli F, Tomasoni LR, Matteelli A.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012064. doi: 10.4084/MJHID.2012.064. Epub 2012 Oct 3.


Plasmodium vivax treatments: what are we looking for?

Price RN, Douglas NM, Anstey NM, von Seidlein L.

Curr Opin Infect Dis. 2011 Dec;24(6):578-85. doi: 10.1097/QCO.0b013e32834c61e3. Review.


A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs.

McCarthy JS, Sekuloski S, Griffin PM, Elliott S, Douglas N, Peatey C, Rockett R, O'Rourke P, Marquart L, Hermsen C, Duparc S, Möhrle J, Trenholme KR, Humberstone AJ.

PLoS One. 2011;6(8):e21914. doi: 10.1371/journal.pone.0021914. Epub 2011 Aug 22.


Vivax malaria: neglected and not benign.

Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM.

Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):79-87. Review.


Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system.

Mather MW, Darrouzet E, Valkova-Valchanova M, Cooley JW, McIntosh MT, Daldal F, Vaidya AB.

J Biol Chem. 2005 Jul 22;280(29):27458-65. Epub 2005 May 24.


Chloroquine resistance in Plasmodium vivax.

Baird JK.

Antimicrob Agents Chemother. 2004 Nov;48(11):4075-83. Review. No abstract available.

Supplemental Content

Support Center